Cancer: Surviving on the edge

Cancer Cell

Volumn 6, Issue 3, 2004, Pages 215-222

  Hahn, William C ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; PROTEIN P53; TAMOXIFEN; TELOMERASE;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMOSOME ABERRATION; CONFERENCE PAPER; ENVIRONMENTAL FACTOR; GENE MUTATION; GROWTH DISORDER; HUMAN; LIFESPAN; NEOPLASM; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; SENESCENCE; STRESS;

EID: 4544248619     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.09.007     Document Type: Conference Paper

References (90)

1. Aguirre A.J., Bardeesy N., Sinha M., Lopez L., Tuveson D.A., Horner J., Redston M.S., DePinho R.A. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 17:2003;3112-3126
2. Armbruster B.N., Linardic C.M., Veldman T., Bansal N.P., Downie D.L., Counter C.M. Rescue of an hTERT mutant defective in telomere elongation by fusion with hPot1. Mol. Cell. Biol. 24:2004;3552-3561
3. Artandi S.E., Chang S., Lee S.-L., Alson S., Gottlieb G.J., Chin L., DePinho R.A. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature. 406:2000;461-465
4. Asai A., Oshima Y., Yamamoto Y., Uochi T.A., Kusaka H., Akinaga S., Yamashita Y., Pongracz K., Pruzan R., Wunder E., et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 63:2003;3931-3939
5. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 421:2003;499-506
6. Bakkenist C.J., Kastan M.B. Initiating cellular stress responses. Cell. 118:2004;9-17
7. Bassing C.H., Suh H., Ferguson D.O., Chua K.F., Manis J., Eckersdorff M., Gleason M., Bronson R., Lee C., Alt F.W. Histone H2AX. A dosage-dependent suppressor of oncogenic translocations and tumors Cell. 114:2003;359-370
8. Baumann P., Cech T.R. Pot1, the putative telomere end-binding protein in fission yeast and humans. Science. 292:2001;1171-1175
9. Bergamaschi D., Samuels Y., O'Neil N.J., Trigiante G., Crook T., Hsieh J.K., O'Connor D.J., Zhong S., Campargue I., Tomlinson M.L., et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat. Genet. 33:2003;162-167
10. Berns K., Hijmans E.M., Mullenders J., Brummelkamp T.R., Velds A., Heimerikx M., Kerkhoven R.M., Madiredjo M., Nijkamp W., Weigelt B., et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature. 428:2004;431-437
11. Bertwistle D., Sugimoto M., Sherr C.J. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol. Cell. Biol. 24:2004;985-996
12. Bodnar A.G., Ouellette M., Frolkis M., Holt S.E., Chiu C.P., Morin G.B., Harley C.B., Shay J.W., Lichtsteiner S., Wright W.E. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:1998;349-352
13. Broccoli D., Young J.W., de Lange T. Telomerase activity in normal and malignant hematopoietic cells. Proc. Natl. Acad. Sci. USA. 92:1995;9082-9086
14. Brummelkamp T.R., Nijman S.M., Dirac A.M., Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature. 424:2003;797-801
15. Celeste A., Difilippantonio S., Difilippantonio M.J., Fernandez-Capetillo O., Pilch D.R., Sedelnikova O.A., Eckhaus M., Ried T., Bonner W.M., Nussenzweig A. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell. 114:2003;371-383
16. Chan S.W., Blackburn E.H. New ways not to make ends meet. Telomerase, DNA damage proteins and heterochromatin Oncogene. 21:2002;553-563
17. Chin L., Artandi S.E., Shen Q., Tam A., Lee S.L., Gottlieb G.J., Greider C.W., DePinho R.A. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell. 97:1999;527-538. a
18. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H., et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:1999;468-472. b
19. Colgin L.M., Baran K., Baumann P., Cech T.R., Reddel R.R. Human POT1 facilitates telomere elongation by telomerase. Curr. Biol. 13:2003;942-946
20. Counter C.M., Avilion A.A., Le Feuvre C.E., Stewart N.G., Greider C.W., Harley C.B., Bacchetti S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11:1992;1921-1929
21. de Lange T. Protection of mammalian telomeres. Oncogene. 21:2002;532-540
22. Demonacos C., Krstic-Demonacos M., La Thangue N.B. A TPR motif cofactor contributes to p300 activity in the p53 response. Mol. Cell. 8:2001;71-84
23. Demonacos C., Krstic-Demonacos M., Smith L., Xu D., O'Connor D.P., Jansson M., La Thangue N.B. A new effector pathway links ATM kinase with the DNA damage response. Nat. Cell Biol. in press:2004
24. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A. Jr., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 356:1992;215-221
25. Dornan D., Wertz I., Shimizu H., Arnott D., Frantz G.D., Dowd P., O'Rourke K., Koeppen H., Dixit V.M. The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature. 429:2004;86-92
26. Drayton S., Rowe J., Jones R., Vatcheva R., Cuthbert-Heavens D., Marshall J., Fried M., Peters G. Tumor suppressor p16INK4a determines sensitivity of human cells to transformation by cooperating cellular oncogenes. Cancer Cell. 4:2003;301-310
27. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411:2001;494-498
28. Flores E.R., Tsai K.Y., Crowley D., Sengupta S., Yang A., McKeon F., Jacks T. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 416:2002;560-564
29. Flores I., Murphy D.J., Swigart L.B., Knies U., Evan G.I. Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene. 23:2004;5923-5930
30. Fu D., Collins K. Distinct biogenesis pathways for human telomerase RNA and H/ACA small nucleolar RNAs. Mol. Cell. 11:2003;1361-1372
31. Garcia-Cao I., Garcia-Cao M., Martin-Caballero J., Criado L.M., Klatt P., Flores J.M., Weill J.C., Blasco M.A., Serrano M. Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21:2002;6225-6235
32. Garcia-Cao M., O'Sullivan R., Peters A.H., Jenuwein T., Blasco M.A. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat. Genet. 36:2004;94-99
33. Gonzalez-Suarez E., Samper E., Flores J.M., Blasco M.A. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat. Genet. 26:2000;114-117
34. Greenberg R.A., Chin L., Femino A., Lee K.H., Gottlieb G.J., Singer R.H., Greider C.W., DePinho R.A. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell. 97:1999;515-525
35. Hahn W.C., Weinberg R.A. Modelling the molecular circuitry of cancer. Nat. Rev. Cancer. 2:2002;331-341
36. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., Weinberg R.A. Creation of human tumor cells with defined genetic elements. Nature. 400:1999;464-468
37. Hakin-Smith V., Jellinek D.A., Levy D., Carroll T., Teo M., Timperley W.R., McKay M.J., Reddel R.R., Royds J.A. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet. 361:2003;836-838
38. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70
39. Harley C.B., Futcher A.B., Greider C.W. Telomeres shorten during ageing of human fibroblasts. Nature. 345:1990;458-460
40. Harley C.B., Kim N.W., Prowse K.R., Weinrich S.L., Hirsch K.S., West M.D., Bacchetti S., Hirte H.W., Counter C.M., Greider C.W., et al. Telomerase, cell immortality, and cancer. Cold Spring Harb. Symp. Quant. Biol. 59:1994;307-315
41. Hastie N.D., Dempster M., Dunlop M.G., Thompson A.M., Green D.K., Allshire R.C. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 346:1990;866-868
42. Hemann M.T., Strong M.A., Hao L.Y., Greider C.W. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell. 107:2001;67-77
43. Hingorani S.R., Petricoin E.F., Maitra A., Rajapakse V., King C., Jacobetz M.A., Ross S., Conrads T.P., Veenstra T.D., Hitt B.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 4:2003;437-450
44. Hofseth L.J., Hussain S.P., Harris C.C. p53. 25 years after its discovery Trends Pharmacol. Sci. 25:2004;177-181
45. Jack M.T., Woo R.A., Motoyama N., Takai H., Lee P.W. DNA-dependent protein kinase and checkpoint kinase 2 synergistically activate a latent population of p53 upon DNA damage. J. Biol. Chem. 279:2004;15269-15273
46. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4:1994;1-7
47. Jackson E.L., Willis N., Mercer K., Bronson R.T., Crowley D., Montoya R., Jacks T., Tuveson D.A. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15:2001;3243-3248
48. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M., Sundberg C.D., Bishop J.M., Felsher D.W. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 297:2002;102-104
49. Johnson L., Mercer K., Greenbaum D., Bronson R.T., Crowley D., Tuveson D.A., Jacks T. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature. 410:2001;1111-1116
50. Kamijo T., Zindy F., Roussel M.F., Quelle D.E., Downing J.R., Ashmun R.A., Grosveld G., Sherr C.J. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 91:1997;649-659
51. Kim N.W., Piatyszek M.A., Prowse K.R., Harley C.B., West M.D., Ho P.L., Coviello G.M., Wright W.E., Weinrich S.L., Shay J.W. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:1994;2011-2015
52. Kitagawa R., Bakkenist C.J., McKinnon P.J., Kastan M.B. Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. Genes Dev. 18:2004;1423-1438
53. Krimpenfort P., Quon K.C., Mooi W.J., Loonstra A., Berns A. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature. 413:2001;83-86
54. Kuo M.-L., den Besten W., Bertwistle D., Roussel M.F., Sherr C.J. N-terminal polyubiquitination and degradation of the Arf tumor suppressor. Genes Dev. 18:2004;1862-1875
55. Kuperwasser C., Chavarria T., Wu M., Magrane G., Gray J.W., Carey L., Richardson A., Weinberg R.A. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc. Natl. Acad. Sci. USA. 101:2004;4966-4971
56. Kwiatkowski D.J. Rhebbing up mTOR. New insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis Cancer Biol. Ther. 2:2003;471-476
57. Levine A.J. The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology. 177:1990;419-426
58. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell. 88:1997;323-331
59. Li B., Oestreich S., de Lange T. Identification of human Rap1. Implications for telomere evolution Cell. 101:2000;471-483
60. Liu D., Safari A., O'Connor M.S., Chan D.W., Laegeler A., Qin J., Songyang Z. PTOP interacts with POT1 and regulates its localization to telomeres. Nat. Cell Biol. 6:2004;673-680
61. Loayza D., De Lange T. POT1 as a terminal transducer of TRF1 telomere length control. Nature. 423:2003;1013-1018
62. Masutomi K., Yu E.Y., Khurts S., Ben-Porath I., Currier J.L., Metz G.B., Brooks M.W., Kaneko S., Murakami S., DeCaprio J.A., et al. Telomerase maintains telomere structure in normal human cells. Cell. 114:2003;241-253
63. Meuwissen R., Linn S.C., Linnoila R.I., Zevenhoven J., Mooi W.J., Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell. 4:2003;181-189
64. Mitchell J.R., Wood E., Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 402:1999;551-555
65. Moberg K.H., Bell D.W., Wahrer D.C., Haber D.A., Hariharan I.K. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature. 413:2001;311-316
66. Moberg K.H., Mukherjee A., Veraksa A., Artavanis-Tsakonas S., Hariharan I.K. The Drosophila F box protein archipelago regulates dMyc protein levels in vivo. Curr. Biol. 14:2004;965-974
67. Nikitina T., Woodcock C.L. Closed chromatin loops at the ends of chromosomes. J. Cell Biol. 166:2004;161-165
68. Opresko P.L., von Kobbe C., Laine J.P., Harrigan J., Hickson I.D., Bohr V.A. Telomere-binding protein TRF2 binds to and stimulates the Werner and Bloom syndrome helicases. J. Biol. Chem. 277:2002;41110-41119
69. Pelengaris S., Khan M., Evan G.I. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 109:2002;321-334
70. Reddel R.R. Alternative lengthening of telomeres, telomerase, and cancer. Cancer Lett. 194:2003;155-162
71. Samuels-Lev Y., O'Connor D.J., Bergamaschi D., Trigiante G., Hsieh J.K., Zhong S., Campargue I., Naumovski L., Crook T., Lu X. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell. 8:2001;781-794
72. Shay J.W., Wright W.E. Quantitation of the frequency of immortalization of normal human diploid fibroblasts by SV40 large T-antigen. Exp. Cell Res. 184:1989;109-118
73. Shay J.W., Pereira-Smith O.M., Wright W.E. A role for both RB and p53 in the regulation of human cellular senescence. Exp. Cell Res. 196:1991;33-39
74. Sherr C.J. The ink4a/arf network in tumour suppression. Nat. Rev. Mol. Cell Biol. 2:2001;731-737
75. Slee E.A., O'Connor D.J., Lu X. To die or not to die. How does p53 decide? Oncogene. 23:2004;2809-2818
76. Steinert S., Shay J.W., Wright W.E. Modification of subtelomeric DNA. Mol. Cell. Biol. 24:2004;4571-4580
77. Takai H., Smogorzewska A., de Lange T. DNA damage foci at dysfunctional telomeres. Curr. Biol. 13:2003;1549-1556
78. Tapon N., Ito N., Dickson B.J., Treisman J.E., Hariharan I.K. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell. 105:2001;345-355
79. Teixeira M.T., Arneric M., Sperisen P., Lingner J. Telomere length homeostasis is achieved via a switch between telomerase- extendible and -nonextendible states. Cell. 117:2004;323-335
80. Vaziri H., Benchimol S. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr. Biol. 8:1998;279-282
81. Voorhoeve P.M., Agami R. The tumor-suppressive functions of the human INK4A locus. Cancer Cell. 4:2003;311-319
82. Wong J.M., Collins K. Telomere maintenance and disease. Lancet. 362:2003;983-988
83. Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R.A., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117:2004;927-939
84. Ye J.Z., Hockemeyer D., Krutchinsky A.N., Loayza D., Hooper S.M., Chait B.T., de Lange T. POT1-interacting protein PIP1. A telomere length regulator that recruits POT1 to the TIN2/TRF1 complex Genes Dev. 18:2004;1649-1654
85. Yeager T.R., Neumann A.A., Englezou A., Huschtscha L.I., Noble J.R., Reddel R.R. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 59:1999;4175-4179
86. Zachos G., Rainey M.D., Gillespie D.A. Chk1-deficient tumour cells are viable but exhibit multiple checkpoint and survival defects. EMBO J. 22:2003;713-723
87. Zhu X.D., Kuster B., Mann M., Petrini J.H., Lange T. Cell-cycle-regulated association of RAD50/MRE11/NBS1 with TRF2 and human telomeres. Nat. Genet. 25:2000;347-352
88. Zhu X.D., Niedernhofer L., Kuster B., Mann M., Hoeijmakers J.H., de Lange T. ERCC1/XPF removes the 3′ overhang from uncapped telomeres and represses formation of telomeric DNA-containing double minute chromosomes. Mol. Cell. 12:2003;1489-1498
89. Zindy F., Eischen C.M., Randle D.H., Kamijo T., Cleveland J.L., Sherr C.J., Roussel M.F. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:1998;2424-2433
90. Zindy F., Williams R.T., Baudino T.A., Rehg J.E., Skapek S.X., Cleveland J.L., Roussel M.F., Sherr C.J. Arf tumor suppressor promoter monitors latent oncogenic signals in vivo. Proc. Natl. Acad. Sci. USA. 100:2003;15930-15935